Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy

Fig. 3

Effectiveness of dabrafenib and trametinib against BRAF V600E-mutant GBM cell lines in vitro. Targeted treatment reduced the viability of NGT41 and other BRAF V600E-mutant glioma cell lines (AM38, DBTRG-05MG) relative to BRAF-wildtype glioma cell lines (U87MG, T98G). (n ≧6, *p < 0.05, **p < 0.01, †p < 0.001, ‡p < 0.0001; Two-way ANOVA) (a). Marked inhibition of phosphorylated MEK and ERK was observed in BRAF V600E-mutant cell lines. The expression of phosphorylated ERK was suppressed by trametinib treatment, regardless of BRAF status (b)

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us